MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    DNA methylation differs between idiopathic Parkinson Disease and Healthy Control subjects in the Parkinson’s Progression Marker Initiative (PPMI) cohort

    P. Gonzalez-Latapi, B. Bustos, T. Simuni, S. Lubbe, D. Krainc (Chicago, USA)

    Objective: Compare baseline whole blood DNA methylation in unmedicated idiopathic Parkinson's Disease (iPD) and healthy control (HC) participants from PPMI Background: Epigenetic mechanisms like DNA…
  • 2022 International Congress

    Longitudinal Exercise is Associated with Reduced Hospitalization Risk in Parkinson’s Disease

    G. Kannarkat, M. Rafferty, S. Luo, H. Liu, K. Mills (Baltimore, USA)

    Objective: To determine if longitudinal exercise and physical therapy (PT) use is associated with reduced risk of hospital encounter in individuals with Parkinson’s disease (iwPD).…
  • 2022 International Congress

    Profiling the biochemical lysosomal activities in blood of patients with LRRK2 G2019S associated Parkinson’s disease

    K. Basharova, A. Bezrukova, I. Miliukhina, A. Timofeeva, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To replicate the previous study of Alcalay and coauthors on estimation of lysosomal enzymes activities [1] with additional estimation of corresponding substrates in patients…
  • 2022 International Congress

    A modified Delphi panel to establish a threshold of meaningful progression on MDS-UPDRS Part III

    D. Trundell, L. Barrett, R. Rogers, E. Davies, S. Zanigni, N. Pross, G. Pagano, T. Nikolcheva, S. Cano (Welwyn Garden City, United Kingdom)

    Objective: To establish a threshold for meaningful progression on MDS-UPDRS Part III in an early-stage Parkinson's disease (PD) population (Hoehn & Yahr [H&Y] Stage I–II)…
  • 2022 International Congress

    Brain effects of high-intensity exercise on the dopamine system in individuals with Parkinson’s disease

    S. Tinaz, B. de Laat, G. Stanley, J. Hoye, J. Key, M. Hespeler, J. Ligi, Y. Huang, N. Nabulsi, E. Morris (New Haven, USA)

    Objective: We used PET imaging with 18F-FE-PE2I to quantify dopamine transporter availability and neuromelanin (NM)-MRI to measure the NM content in the substantia nigra (SN)…
  • 2022 International Congress

    NIMHANS Neuropsychological Battery for Elderly in Parkinson’s disease patients: Validation and diagnosis using MDS PD-MCI task force criteria in Indian population

    R. Yadav, R. Botta, K. Kumar, BM. Kutty, A. Mahadevan, PK. Pal (Bengaluru, India)

    Objective: To validate NIMHANS Neuropsychological Battery for Elderly( NNB-E) and evaluate cognitive impairment in Parkinson's disease (PD) patients in comparison with healthy controls. Background: Cognitive…
  • 2022 International Congress

    Early Synucleinopathy is Associated with Differential Regulation of Neurotransmission and Immune Related Genes

    J. Patterson, J. Kochmanski, A. Stoll, M. Kubik, C. Kemp, J. Howe, M. Duffy, K. Miller, A. Cole-Strauss, J. Beck, S. Counts, K. Steece-Collier, A. Bernstein, K. Luk, C. Sortwell (Grand Rapids, USA)

    Objective: Identification of gene expression changes in the rat substantia nigra pars compacta (SNpc) associated with early alpha-synuclein (a-syn) inclusion formation. Background: Accumulation of intracellular…
  • 2022 International Congress

    Antipsychotic use in Parkinson’s disease: a single center retrospective chart review

    S. Brooker, C. Yeh, D. Larson (Chicago, USA)

    Objective: To assess the prevalence of antipsychotic (AP) use in people with Parkinson’s disease (PwP), and identify factors associated with AP prescription and differences in…
  • 2022 International Congress

    A double-blind randomized clinical trial to evaluate the effects of Candesartan for Cognitive and Neuropsychiatric Impairment in Parkinson’s Disease

    J. Kulisevsky, S. Martinez-Horta, A. Campolongo, B. Pascual-Sedano, J. Marin-Lahoz, H. Bejr-Kasem, A. Puig-Davi, J. Pagonabarraga, J. Rodriguez-Antiguedad (Barcelona, Spain)

    Objective: To explore the feasibility of repurposing candesartan for the treatment of cognitive impairment and neuropsychiatric symptoms in PD. Background: There is an urgent need…
  • 2022 International Congress

    Parkinson`s disease in Pandemic Covid

    S. Galbineanu, A. Ailene (Brasov, Romania)

    Objective: SARS-CoV2 infection invades the brain through ACE2 receptors or the cytotoxic aggregation of proteins, including α-synuclein.Studies are uncertain on the risk of COVID and…
  • « Previous Page
  • 1
  • …
  • 194
  • 195
  • 196
  • 197
  • 198
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley